Contraceptive Technology Update – September 1, 2008
September 1, 2008
View Issues
-
Four-week delay feasible for DMPA reinjection — will protocols change?
Extending the current grace period for reinjection of the contraceptive shot depot medroxyprogesterone acetate (DMPA, Depo-Provera, Pfizer) from two to four weeks does not increase pregnancy risk and could increase contraceptive continuation, indicate findings from a newly published study. -
Check for problems with oral rapid HIV tests
If your clinic is using oral fluid samples for rapid HIV testing, be sure to monitor for false-positive results. -
HPV vaccine: Will U.S. see second vaccine?
Regulatory review of a second human papillomavirus (HPV) vaccine has been delayed. GlaxoSmithKline has announced plans to submit additional data from its large-scale clinical trial for its vaccine candidate, Cervarix. -
Agency widens access to use of female condoms
The woman in your next examination room tells you she has a long-term partner who has multiple sexual contacts. While she says she is concerned about protection against HIV, she admits she cannot convince her partner to use a male condom. What is your next move? -
Guidance updated on use of hormone therapy
Add a new resource on menopause management to your clinical practice. The North American Menopause Society (NAMS) has just updated its guidelines on postmenopausal hormone therapy. -
Increase the radar for STDs in seniors
If your practice includes care of those ages 45 and older, be prepared to discuss risk of sexually transmitted disease (STD) infection.